CA2128205C - Methotrexate derivatives - Google Patents
Methotrexate derivatives Download PDFInfo
- Publication number
- CA2128205C CA2128205C CA002128205A CA2128205A CA2128205C CA 2128205 C CA2128205 C CA 2128205C CA 002128205 A CA002128205 A CA 002128205A CA 2128205 A CA2128205 A CA 2128205A CA 2128205 C CA2128205 C CA 2128205C
- Authority
- CA
- Canada
- Prior art keywords
- general formula
- compound
- carbon atoms
- lower alkyl
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical class C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 179
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 46
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 44
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 40
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 10
- 239000003435 antirheumatic agent Substances 0.000 claims abstract description 6
- 229910006069 SO3H Inorganic materials 0.000 claims abstract 7
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims abstract 7
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 108
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 18
- 230000003356 anti-rheumatic effect Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 129
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 111
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 110
- 238000006243 chemical reaction Methods 0.000 description 103
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 102
- 239000002904 solvent Substances 0.000 description 98
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 90
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 68
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 65
- 239000007795 chemical reaction product Substances 0.000 description 61
- 238000005160 1H NMR spectroscopy Methods 0.000 description 57
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 57
- 239000007864 aqueous solution Substances 0.000 description 57
- 238000003756 stirring Methods 0.000 description 56
- 238000003786 synthesis reaction Methods 0.000 description 56
- 230000015572 biosynthetic process Effects 0.000 description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 239000000725 suspension Substances 0.000 description 33
- 238000001816 cooling Methods 0.000 description 31
- 235000017557 sodium bicarbonate Nutrition 0.000 description 30
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 30
- -1 p-toluenesulfonyl group Chemical group 0.000 description 29
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 25
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 24
- 238000001914 filtration Methods 0.000 description 23
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- 229910052938 sodium sulfate Inorganic materials 0.000 description 22
- 235000011152 sodium sulphate Nutrition 0.000 description 22
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 21
- 238000000605 extraction Methods 0.000 description 21
- 239000010410 layer Substances 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 239000002244 precipitate Substances 0.000 description 19
- 229920006395 saturated elastomer Polymers 0.000 description 19
- 238000010898 silica gel chromatography Methods 0.000 description 19
- 238000010828 elution Methods 0.000 description 18
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 17
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- 229910000027 potassium carbonate Inorganic materials 0.000 description 14
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 230000003197 catalytic effect Effects 0.000 description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
- 235000019341 magnesium sulphate Nutrition 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 238000000926 separation method Methods 0.000 description 11
- 239000012299 nitrogen atmosphere Substances 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- KMQIBGKVZDBGAH-UHFFFAOYSA-N 6-(bromomethyl)pteridine-2,4-diamine;hydrobromide Chemical compound Br.N1=C(CBr)C=NC2=NC(N)=NC(N)=C21 KMQIBGKVZDBGAH-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 8
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229960002989 glutamic acid Drugs 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 229960000485 methotrexate Drugs 0.000 description 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 238000010979 pH adjustment Methods 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- HERPVHLYIHBEFW-ZETCQYMHSA-N diethyl (2s)-2-aminopentanedioate Chemical compound CCOC(=O)CC[C@H](N)C(=O)OCC HERPVHLYIHBEFW-ZETCQYMHSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- XDTTUTIFWDAMIX-UHFFFAOYSA-N 3-methyl-4-nitrobenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1[N+]([O-])=O XDTTUTIFWDAMIX-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102000020897 Formins Human genes 0.000 description 2
- 108091022623 Formins Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 2
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- AHSBSUVHXDIAEY-UHFFFAOYSA-K manganese(iii) acetate Chemical compound [Mn+3].CC([O-])=O.CC([O-])=O.CC([O-])=O AHSBSUVHXDIAEY-UHFFFAOYSA-K 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- LELRWENMUDOZSQ-UHFFFAOYSA-N 1-(7-methyl-2,3-dihydroindol-1-yl)ethanone Chemical compound C1=CC(C)=C2N(C(=O)C)CCC2=C1 LELRWENMUDOZSQ-UHFFFAOYSA-N 0.000 description 1
- OXDAWXQIBJRGRD-UHFFFAOYSA-N 1-acetyl-7-methyl-2,3-dihydroindole-5-carbonitrile Chemical compound N#CC1=CC(C)=C2N(C(=O)C)CCC2=C1 OXDAWXQIBJRGRD-UHFFFAOYSA-N 0.000 description 1
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- OQZGYMRYZAKXAF-UHFFFAOYSA-N 2-(4-methylcyclohexyl)acetic acid Chemical compound CC1CCC(CC(O)=O)CC1 OQZGYMRYZAKXAF-UHFFFAOYSA-N 0.000 description 1
- VCJSRDBDCVROQC-UHFFFAOYSA-N 2-[[4-[(2,4-diaminopteridin-6-yl)methylamino]-3-methylbenzoyl]amino]pentanedioic acid Chemical compound CC1=CC(C(=O)NC(CCC(O)=O)C(O)=O)=CC=C1NCC1=CN=C(N=C(N)N=C2N)C2=N1 VCJSRDBDCVROQC-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- HYIGQVBSJWENBV-UHFFFAOYSA-N 3,5-dimethyl-4-[methyl(phenylmethoxycarbonyl)amino]benzoic acid Chemical compound CC=1C=C(C(O)=O)C=C(C)C=1N(C)C(=O)OCC1=CC=CC=C1 HYIGQVBSJWENBV-UHFFFAOYSA-N 0.000 description 1
- JPVYZMODKOYQRO-UHFFFAOYSA-N 3-ethyl-4-[methyl-(4-methylphenyl)sulfonylamino]benzoic acid Chemical compound CCC1=CC(C(O)=O)=CC=C1N(C)S(=O)(=O)C1=CC=C(C)C=C1 JPVYZMODKOYQRO-UHFFFAOYSA-N 0.000 description 1
- DGLLZNHDQKJWNY-UHFFFAOYSA-N 3-methyl-4-(methylamino)benzoic acid Chemical compound CNC1=CC=C(C(O)=O)C=C1C DGLLZNHDQKJWNY-UHFFFAOYSA-N 0.000 description 1
- YWEMBZPSYGFVOH-UHFFFAOYSA-N 3-methyl-4-(phenylmethoxycarbonylamino)benzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1NC(=O)OCC1=CC=CC=C1 YWEMBZPSYGFVOH-UHFFFAOYSA-N 0.000 description 1
- KWKNDEGTCRAUGG-UHFFFAOYSA-N 3-methyl-4-[methyl(phenylmethoxycarbonyl)amino]benzoic acid Chemical compound C=1C=C(C(O)=O)C=C(C)C=1N(C)C(=O)OCC1=CC=CC=C1 KWKNDEGTCRAUGG-UHFFFAOYSA-N 0.000 description 1
- UOAIMKYNXAOFBT-UHFFFAOYSA-N 4-[ethyl(phenylmethoxycarbonyl)amino]-3-methylbenzoic acid Chemical compound C=1C=C(C(O)=O)C=C(C)C=1N(CC)C(=O)OCC1=CC=CC=C1 UOAIMKYNXAOFBT-UHFFFAOYSA-N 0.000 description 1
- IAZPRLGHHDCVLM-UHFFFAOYSA-N 4-amino-3-methylbenzoic acid 3-methyl-4-(phenylmethoxycarbonylamino)benzoic acid Chemical compound NC1=C(C=C(C(=O)O)C=C1)C.C(=O)(OCC1=CC=CC=C1)NC1=C(C=C(C(=O)O)C=C1)C IAZPRLGHHDCVLM-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- ZDMDLAOHGIAROM-UHFFFAOYSA-N 6-(2-bromoethyl)pteridine-2,4-diamine;hydrobromide Chemical compound Br.N1=C(CCBr)C=NC2=NC(N)=NC(N)=C21 ZDMDLAOHGIAROM-UHFFFAOYSA-N 0.000 description 1
- BAWJKRIJIUBSLQ-UHFFFAOYSA-N 7-bromo-6-(bromomethyl)pteridine-2,4-diamine Chemical compound N1=C(CBr)C(Br)=NC2=NC(N)=NC(N)=C21 BAWJKRIJIUBSLQ-UHFFFAOYSA-N 0.000 description 1
- STHGUCBFJMQBJI-UHFFFAOYSA-N 7-methyl-1-phenylmethoxycarbonyl-2,3-dihydroindole-5-carboxylic acid Chemical compound C1=2C(C)=CC(C(O)=O)=CC=2CCN1C(=O)OCC1=CC=CC=C1 STHGUCBFJMQBJI-UHFFFAOYSA-N 0.000 description 1
- WHPDSANSNOUOLZ-UHFFFAOYSA-N 7-methyl-2,3-dihydro-1h-indole Chemical compound CC1=CC=CC2=C1NCC2 WHPDSANSNOUOLZ-UHFFFAOYSA-N 0.000 description 1
- DBZHABBLOUVFBZ-UHFFFAOYSA-N 7-methyl-2,3-dihydro-1h-indole-5-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC2=C1NCC2 DBZHABBLOUVFBZ-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- CPQAYCKAPBVIEP-UHFFFAOYSA-N azane;n,n-diethylethanamine Chemical compound N.CCN(CC)CC CPQAYCKAPBVIEP-UHFFFAOYSA-N 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- BREIOMRLEAGJMD-LURJTMIESA-N dimethyl (2s)-2-aminohexanedioate Chemical compound COC(=O)CCC[C@H](N)C(=O)OC BREIOMRLEAGJMD-LURJTMIESA-N 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- IHSLHAZEJBXKMN-UHFFFAOYSA-L potassium nitrosodisulfonate Chemical compound [K+].[K+].[O-]S(=O)(=O)N([O])S([O-])(=O)=O IHSLHAZEJBXKMN-UHFFFAOYSA-L 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5305192 | 1992-01-27 | ||
| JP53051/1992 | 1992-01-27 | ||
| JP75106/1992 | 1992-02-13 | ||
| JP7510692 | 1992-02-13 | ||
| JP10832092 | 1992-03-16 | ||
| JP108320/1992 | 1992-03-16 | ||
| JP115126/1992 | 1992-03-24 | ||
| JP11512692 | 1992-03-24 | ||
| PCT/JP1993/000096 WO1993015077A1 (fr) | 1992-01-27 | 1993-01-27 | Derive de methotrexate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2128205A1 CA2128205A1 (en) | 1993-08-05 |
| CA2128205C true CA2128205C (en) | 2004-03-30 |
Family
ID=27462860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002128205A Expired - Fee Related CA2128205C (en) | 1992-01-27 | 1993-01-27 | Methotrexate derivatives |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6559149B1 (OSRAM) |
| EP (1) | EP0632038B1 (OSRAM) |
| KR (1) | KR100248324B1 (OSRAM) |
| AT (1) | ATE204576T1 (OSRAM) |
| AU (1) | AU3367693A (OSRAM) |
| CA (1) | CA2128205C (OSRAM) |
| DE (1) | DE69330639T2 (OSRAM) |
| ES (1) | ES2161713T3 (OSRAM) |
| TW (1) | TW223637B (OSRAM) |
| WO (1) | WO1993015077A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2128205C (en) * | 1992-01-27 | 2004-03-30 | Hiroharu Matsuoka | Methotrexate derivatives |
| KR100259742B1 (ko) * | 1992-12-25 | 2000-07-01 | 나가야마 오사무 | 메토트렉세이트 유도체 |
| US5958928A (en) * | 1995-03-27 | 1999-09-28 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical agents containing methotrexate derivative |
| US7276506B2 (en) * | 1998-12-28 | 2007-10-02 | 4 Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
| US7229986B2 (en) | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
| US20070032477A1 (en) * | 2003-10-17 | 2007-02-08 | Waer Mark J A | Pteridine derivatives useful for making pharmaceutical compositions |
| US20060039985A1 (en) * | 2004-04-27 | 2006-02-23 | Bennett David B | Methotrexate compositions |
| US7601834B2 (en) * | 2005-02-22 | 2009-10-13 | Savvipharm Inc | Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives |
| NZ568288A (en) | 2005-11-28 | 2012-02-24 | Verrow Pharmaceuticals Inc | Compositions comprising a a cyclodextrin and a nephrotoxic anticancer drug |
| WO2007098089A2 (en) * | 2006-02-17 | 2007-08-30 | Novacea, Inc. | Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs |
| US9259426B2 (en) | 2006-07-20 | 2016-02-16 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| WO2008009079A2 (en) * | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
| JP5693950B2 (ja) | 2007-04-11 | 2015-04-01 | メルク エ カンパニー | １８ｆ標識葉酸 |
| KR101657323B1 (ko) | 2008-11-19 | 2016-09-13 | 포라 가세이 고교 가부시키가이샤 | 주름 개선제 |
| EP3722297A1 (en) | 2015-03-04 | 2020-10-14 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| ES2906581T3 (es) | 2016-09-02 | 2022-04-19 | Gilead Sciences Inc | Compuestos moduladores de los receptores tipo Toll |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI812775A7 (fi) * | 1980-09-12 | 1982-03-13 | Farmos Oy | Menetelmä N-/4-/(2,4-diamino-6- pteridinyyli)-metyyli/- metyyliamino/bentsoyyli/glutamiinihapon ja senjohdannaisten valmistamiseksi. |
| US4490529A (en) * | 1983-09-06 | 1984-12-25 | Dana-Farber Cancer Institute, Inc. | Cysteic acid and homocysteic acid analogues of methotrexate and aminopterin |
| ATE187455T1 (de) * | 1990-08-14 | 1999-12-15 | Chugai Pharmaceutical Co Ltd | Methotrexatderivate mit antirheumatischer aktivität |
| JP3124592B2 (ja) * | 1990-08-14 | 2001-01-15 | 中外製薬株式会社 | 新規メトトレキセート誘導体 |
| JP3207285B2 (ja) * | 1992-01-27 | 2001-09-10 | 中外製薬株式会社 | 新規メトトレキセート誘導体 |
| CA2128205C (en) * | 1992-01-27 | 2004-03-30 | Hiroharu Matsuoka | Methotrexate derivatives |
| JP3274532B2 (ja) * | 1992-03-24 | 2002-04-15 | 中外製薬株式会社 | 抗リウマチ剤 |
-
1993
- 1993-01-27 CA CA002128205A patent/CA2128205C/en not_active Expired - Fee Related
- 1993-01-27 ES ES93902536T patent/ES2161713T3/es not_active Expired - Lifetime
- 1993-01-27 TW TW082100448A patent/TW223637B/zh active
- 1993-01-27 EP EP93902536A patent/EP0632038B1/en not_active Expired - Lifetime
- 1993-01-27 US US08/256,441 patent/US6559149B1/en not_active Expired - Fee Related
- 1993-01-27 KR KR1019940702559A patent/KR100248324B1/ko not_active Expired - Fee Related
- 1993-01-27 DE DE69330639T patent/DE69330639T2/de not_active Expired - Fee Related
- 1993-01-27 AU AU33676/93A patent/AU3367693A/en not_active Abandoned
- 1993-01-27 AT AT93902536T patent/ATE204576T1/de active
- 1993-01-27 WO PCT/JP1993/000096 patent/WO1993015077A1/ja not_active Ceased
-
2003
- 2003-03-03 US US10/376,711 patent/US20030171376A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69330639D1 (de) | 2001-09-27 |
| US20030171376A1 (en) | 2003-09-11 |
| WO1993015077A1 (fr) | 1993-08-05 |
| DE69330639T2 (de) | 2002-07-04 |
| CA2128205A1 (en) | 1993-08-05 |
| KR100248324B1 (ko) | 2000-04-01 |
| AU3367693A (en) | 1993-09-01 |
| ATE204576T1 (de) | 2001-09-15 |
| EP0632038A1 (en) | 1995-01-04 |
| US6559149B1 (en) | 2003-05-06 |
| TW223637B (OSRAM) | 1994-05-11 |
| EP0632038A4 (en) | 1995-02-22 |
| ES2161713T3 (es) | 2001-12-16 |
| EP0632038B1 (en) | 2001-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2128205C (en) | Methotrexate derivatives | |
| AU592271B2 (en) | Anti-cancer quinazoline derivatives | |
| EP0031237A1 (en) | Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents | |
| RU2266280C2 (ru) | Замещенные производные n-бензилиндол-3-ил-глиоксиловой кислоты, обладающие противоопухолевым действием (варианты), их кислотно-аддитивные соли (варианты), фармацевтический препарат, фармацевтическая форма | |
| US5128345A (en) | Carcinostatic composition comprising indolquinolines | |
| US5703089A (en) | Dihydrodibenzisoquinolinediones | |
| KR20010013158A (ko) | 세포 증식 억제제로서의 시아노구아니딘 | |
| Jaycox et al. | Potential DNA bis‐intercalating agents: Synthesis and antitumor activity of novel, conformationally restricted bis (9‐aminoacridines) | |
| US4992444A (en) | Antifolate agents | |
| US7728000B2 (en) | Substituted quinolines for the treatment of cancer | |
| US3028387A (en) | Dialkylaminoalkylaminopteridine derivatives | |
| JP3207285B2 (ja) | 新規メトトレキセート誘導体 | |
| US4892939A (en) | Oligopeptidyl-5-fluorouridine compounds and process for preparing the same | |
| Rosowsky et al. | Synthesis and biological activity of the 2-desamino and 2-desamino-2-methyl analogs of aminopterin and methotrexate | |
| JPH08231514A (ja) | フェニルベンズイミダゾール誘導体 | |
| JPH0616670A (ja) | 抗リウマチ剤 | |
| JPH05194517A (ja) | ６−メルカプトプリン誘導体及びその製法 | |
| US2577039A (en) | Substituted pteridines and method of preparing the same | |
| JP3145533B2 (ja) | 新規メトトレキセート誘導体 | |
| AU619124B2 (en) | Salts of n5,n10-methylene-5,6,7,8-tetrahydrofolic acid | |
| CN117247374A (zh) | 一种bcl-xl抑制剂及其制药用途 | |
| JPS61225186A (ja) | ５−オクソ−ピリド〔４，３−ｄ〕ピリミジン誘導体、その製造方法および用途 | |
| Gangjee et al. | Bicyclic Conformationally Restricted Analogs of Nonclassical Pyrido [2, 3-d] Pyrevddines as Potential Inhibitors of Dihydrofolate Reductases | |
| Aymamí et al. | Substituted Quinolines for the Treatment of Cancer | |
| JPS6248659A (ja) | フエニレン基を有するスパガリン関連ニトリル化合物及びその製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |